Shomit Sengupta

Shomit Sengupta has a strong background in the field of biology and drug development. Shomit is currently the Vice President and Head of Biology at Atavistik Bio, where they are responsible for leading the company's drug discovery platform for the identification of metabolite-protein interactions. Prior to this role, they were the Senior Director and Head of Biology at Atavistik Bio, where they played a key role in securing Series A funding and developing the company's drug discovery platform.

Before joining Atavistik Bio, Shomit held various positions at Agios Pharmaceuticals, including Director and Associate Director. During their time at Agios, they contributed to the development of drug programs and played a role in advancing compounds derived from phenotypic and target-based screens.

Shomit also has experience working at Navitor Pharmaceuticals as a Senior Scientist II, where they helped establish multiple drug development programs and led the NV-5138 program from establishing new biology to IND and licensing to Supernus.

In addition, they worked as a Research Scientist at the Broad Institute, where they led multiple cell-pharmacology programs and collaborated with various research platforms. Prior to that, they were a Senior Scientist at Catabasis Pharmaceuticals, Inc., and a Post-doctoral Fellow at Harvard Medical School, focusing on tumor progression and matrix attachment signaling pathways.

Shomit's academic background includes being a Graduate Student at the Whitehead Institute, where they studied the role of mammalian target of rapamycin complex 1 (mTORC1) in hepatic fatty acid metabolism and aging. Shomit also conducted research as a Research Technician at MIT/Koch Institute.

Overall, Shomit Sengupta has extensive experience in biology, drug development, and leading research programs at various organizations.

Shomit Sengupta completed their Bachelor of Arts degree in Neurobiology from Northwestern University, where they studied from 1995 to 1999. Continuing their academic pursuits, they then attended the prestigious Massachusetts Institute of Technology (MIT) from 2003 to 2010. At MIT, they successfully obtained their Ph.D. in Biology, further expanding their knowledge and expertise in the field.